Please login or register first to view this content.
News
NEWS
LATEST NEWS
Reduced-Intensity Conditioning May Not Improve Post Allogeneic HSCT Outcomes in AML
Uncertainties Surround Optimal Dosing of Cytarabine in AML
Dexamethasone May Not Improve Outcomes in Chronic Subdural Hematoma
Outcomes of Adding a Fourth Chemotherapy Course in AML
PARP Inhibition Associated With Increased Risk for Secondary MDS, AML
Idelalisib Does Not Increase Risk for Bleeding in Patients With CLL, Indolent NHL Receiving Anticoagulation/Antiplatelet Therapy
UPCOMING MEETINGS
December 5 – 8, 2020
62ND ASH ANNUAL MEETING AND EXPOSITION
San Diego Convention Center, San Diego, CA
DRUG NEWS FROM MPR
IV Iron Products: Adverse Events, Associated Costs Compared
FDA: More Data on Remestemcel-L for Graft-vs-Host Disease Needed
FDA Requires Boxed Warning Update for Benzodiazepines
FDA Approves New Treatment Option for Multiple Myeloma
Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication
Esperoct Now Available for Treatment of Hemophilia A
Bomedemstat Receives Fast Track Status for Essential Thrombocythemia
Avatrombopag Designated Orphan Drug for Chemo-Induced Thrombocytopenia
Adakveo Approved for Sickle Cell Disease
FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma
-
Loading...
-
Loading...
Want to read more?
Next post in General Hematology
